ELQ-300 is primarily investigated for its potential as an antimalarial agent. It targets the parasite's mitochondrial electron transport chain, effectively inhibiting its growth and replication. This mechanism makes it a promising candidate for treating drug-resistant strains of malaria, particularly Plasmodium falciparum. Its long half-life and ability to act at multiple stages of the parasite's life cycle enhance its therapeutic potential. Research is ongoing to evaluate its efficacy in clinical trials and explore its use in combination therapies to combat malaria more effectively. Additionally, studies are examining its safety profile and potential applications in other parasitic infections.